2013-08-15 17:33:02 -
KVISTGAARD, Denmark - August 15, 2013 - Bavarian Nordic A/S (OMX: BAVA, OTC:
BVNRY) will announce its 2013 first half results on Thursday, August 22, 2013.
The company will host a conference call at 2:00 pm CET (8:00 am EDT) on the same
day. President and CEO, Anders Hedegaard will present the interim results
followed by a Q&A session with participation of the Company's executive
Dial-in numbers for the conference call are:
Denmark: +45 32 72 80 18
UK: +44 (0) 844 571 8957
USA: +1 866 682 8490
A webcast of the conference call will be broadcasted simultaneously at
www.bavarian-nordic.com/webcast. On this page, the accompanying presentation
will be available prior to the conference call.
Rolf Sass Sørensen, Vice President Investor Relations & Communications
Phone: +45 33 26 83 83
About Bavarian Nordic
is an international biotechnology company developing and
manufacturing novel cancer immunotherapies and vaccines for infectious diseases.
Lead product candidates are PROSTVAC®, an immunotherapy product candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3
clinical trial and IMVAMUNE®, a non-replicating smallpox vaccine candidate in
Phase 3 development, which is being developed and supplied for emergency use to
the U.S. Strategic National Stockpile under a contract with the U.S. Government.
IMVAMUNE is approved in the European Union under the trade name IMVANEX®.
Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol
BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level
1 ADR program listed in the US (OTC) under the symbol BVNRY.
For more information, visit www.bavarian-nordic.com.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bavarian Nordic A/S via Thomson Reuters ONE